A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.

Infection and Immunity
A I FattomR Naso

Abstract

The efficacy of capsular polysaccharide (CP)-specific antibodies elicited by active immunization with vaccines composed of Staphylococcus aureus types 5 and 8 CP linked to Pseudomonas aeruginosa exoprotein A or with immune immunoglobulin G (I-IgG) obtained from vaccinated plasma donors was tested in lethal and sublethal bacterial mouse challenge models. A dose of 2 x 10(5) CFU of S. aureus type 5 CP per mouse administered intraperitoneally (i.p.) with 5% hog mucin was found to cause 80 to 100% mortality in BALB/c mice within 2 to 5 days. Mice passively immunized i.p. 24 h earlier or subcutaneously 48 h earlier with 0.5 ml of I-IgG showed significantly higher average survival rates than animals receiving standard IgG or saline (P < 0.01) following the bacterial challenge. Animals actively immunized with the monovalent type 5 CP-P. aeruginosa exoprotein A conjugate showed a survival rate of 73% compared with 13% in phosphate-buffered saline-immunized animals. The prechallenge geometric mean titer of type 5 CP antibodies in animals that died was significantly (P < 0.05) lower than that of animals which survived the challenge (95.7 versus 223.6 micrograms/ml, respectively). The IgG was further evaluated in mice challenged i.p. with...Continue Reading

References

Aug 1, 1979·Journal of Medical Microbiology·K YoshidaC L San Clemente
Feb 1, 1991·Applied and Environmental Microbiology·W T StringfellowJ M Fournier
May 1, 1990·The Journal of Infectious Diseases·J B Robbins, R Schneerson
Jul 1, 1990·Carbohydrate Research·M MoreauW F Vann
Sep 1, 1987·Annales De L'Institut Pasteur. Microbiology·J M FournierW F Vann
Apr 1, 1988·The Journal of Infectious Diseases·J C LeeG B Pier
Dec 1, 1987·Infection and Immunity·D P GreenbergA S Bayer
Dec 1, 1987·The Journal of Infectious Diseases·R D Arbeit, R M Dunn
Feb 1, 1987·The Journal of Infectious Diseases·R D Arbeit, M J Nelles
Oct 10, 1985·Journal of Immunological Methods·A SuttonR Schneerson
Sep 1, 1985·Journal of Clinical Microbiology·W W KarakawaJ B Robbins
Aug 1, 1974·Infection and Immunity·M A MellyJ H Hash
Jul 23, 1965·Annals of the New York Academy of Sciences·M G Koenig, M A Melly
Jul 23, 1965·Annals of the New York Academy of Sciences·D E Rogers, M A Melly
Apr 1, 1984·Diagnostic Microbiology and Infectious Disease·R D ArbeitJ B Robbins
Jul 1, 1984·Infection and Immunity·J M FournierW W Karakawa
Mar 1, 1984·Journal of Dairy Science·K YoshidaW B Evans
Oct 1, 1961·The Australian Journal of Experimental Biology and Medical Science·S FISHER

❮ Previous
Next ❯

Citations

Jan 25, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Michael Otto
Nov 5, 2015·Expert Opinion on Investigational Drugs·Cuong VuongMichael Otto
Jan 18, 2002·Infection and Immunity·Thanh LuongChia Y Lee
Nov 28, 2001·Current Infectious Disease Reports·Jean C. Lee
Jul 5, 2005·Expert Opinion on Investigational Drugs·R K Sood, A Fattom
Apr 30, 2003·Journal of Molecular Recognition : JMR·Elizabeth Hong-Geller, Goutam Gupta
Jan 26, 2008·FEMS Immunology and Medical Microbiology·Damian C MellesAlex van Belkum
Mar 24, 2006·FEMS Immunology and Medical Microbiology·Sanae SasakiAkio Nakane
Jul 25, 2006·Infection and Immunity·Mohammad R PourmandSimon J Foster
Jun 10, 2010·Expert Opinion on Biological Therapy·Michael Otto
Aug 28, 2012·Human Vaccines & Immunotherapeutics·Annaliesa S AndersonKathrin U Jansen
Sep 15, 2011·Immunotherapy·Nelianne J VerkaikAlex van Belkum
Jul 8, 2014·Nature Reviews. Microbiology·Wilmara Salgado-Pabón, Patrick M Schlievert
Jan 17, 2004·Clinical Microbiology Reviews·Katherine O'Riordan, Jean C Lee
Feb 15, 2002·The New England Journal of Medicine·Henry ShinefieldRobert Naso
Aug 26, 1998·The New England Journal of Medicine·F D Lowy
May 25, 2011·Expert Review of Vaccines·Jane BroughanAnnaliesa S Anderson
Oct 14, 2005·Expert Review of Vaccines·Henry R Shinefield, Steven Black
Dec 20, 2012·Human Vaccines & Immunotherapeutics·Jasdeep S NanraAnnaliesa S Anderson
Apr 13, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G JacobssonR Möllby
Feb 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Isabelle Bekeredjian-DingGunther Hartmann
Jun 26, 2013·Human Vaccines & Immunotherapeutics·Gerald B Pier
Aug 28, 2013·Antimicrobial Agents and Chemotherapy·Joshua B ParsonsCharles O Rock
Feb 18, 2016·EMBO Reports·Tamara Reyes-RoblesVictor J Torres
Apr 7, 2006·Journal of Perinatology : Official Journal of the California Perinatal Association·D K BenjaminUNKNOWN S. aureus prevention investigators
Jul 16, 2002·Infection and Immunity·Tomás Maira-LitránGerald B Pier
Jun 4, 2004·Expert Opinion on Investigational Drugs·Joseph M Patti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.